Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Terns Pharmaceuticals (NASDAQ: TERN) said senior management will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink, Barclays, and The Citizens Life Sciences conferences. Live fireside chat webcasts and replays will be available on the company's investor relations site for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – TERN
In the Feb 26 session, TERN declined 1.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Inducement grants | Neutral | +6.4% | Equity options granted to new employees under inducement award plan. |
| Jan 07 | Conference priorities | Positive | -5.6% | Outlined 2026 priorities and detailed TERN-701 clinical and cash runway plans. |
| Jan 02 | Inducement grants | Neutral | -2.3% | Stock options granted to new employees under Nasdaq Listing Rule 5635(c)(4). |
| Dec 11 | Offering closing | Neutral | +5.6% | Closed underwritten public offering including full exercise of underwriters’ option. |
| Dec 09 | Offering pricing | Neutral | +5.8% | Priced upsized public offering of common stock at $40.00 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has included equity offerings and inducement grants, with generally positive or moderate price responses, suggesting the stock has absorbed financing and compensation-related events without consistent downside pressure.
Over the last few months, Terns has focused on financing, corporate actions, and program visibility. In December 2025, it priced and then closed a sizable public offering at $40.00 per share, with gross proceeds of $650 million and then $747.5 million, both followed by mid-single-digit percentage gains. Early 2026 brought multiple inducement and director option grants tied to Nasdaq rules and board compensation, with mixed but contained price reactions. A January J.P. Morgan presentation outlined detailed 2026 priorities and TERN‑701 milestones, showing an execution focus that contextualizes today’s investor-conference participation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.
TD Cowen's 46th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA
Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL
Barclays 28th Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: Tuesday, March 10, 2026
Location: Miami, FL
The Citizens Life Sciences Conference
Format: Fireside Chat
Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET
Location: Miami, FL
Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
